Neurocrine Biosciences (NBIX) Share-based Compensation (2010 - 2026)

Neurocrine Biosciences has reported Share-based Compensation for 17 years, with the latest figure at $57.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 8.33% year-over-year to $57.2 million; the trailing twelve-month figure through Mar 2026 stood at $222.3 million (up 9.08% YoY), and the FY2025 full-year result was $217.9 million, up 11.46% from the prior year.
• Share-based Compensation for Q1 2026 stood at $57.2 million, down from $58.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $68.5 million in Q2 2023, with the low at $37.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $49.3 million across 5 years, with a median of $47.8 million in 2023.
• The largest YoY upside for Share-based Compensation was 74.28% in 2024 against a maximum downside of 37.08% in 2024.
• Neurocrine Biosciences' Share-based Compensation stood at $43.5 million in 2022, then declined by 12.41% to $38.1 million in 2023, then soared by 74.28% to $66.4 million in 2024, then decreased by 11.75% to $58.6 million in 2025, then fell by 2.39% to $57.2 million in 2026.
• The last three Share-based Compensation figures came in at $57.2 million (Q1 2026), $58.6 million (Q4 2025), and $53.7 million (Q3 2025), per Business Quant data.